NAVB
Navidea Biopharmaceuticals Inc.
NAVB
NAVB
Delisted
NAVB was delisted on the 5th of October, 2023.
28 hedge funds and large institutions have $772K invested in Navidea Biopharmaceuticals Inc. in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Holders
28
Holding in Top 10
–
Calls
$142K
Puts
$114K
Top Buyers
| 1 | +$11.1K | |
| 2 | +$8.39K | |
| 3 | +$5.65K | |
| 4 |
JP Morgan Chase
New York
|
+$5.14K |
| 5 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$2.18K |
Top Sellers
| 1 | -$20K | |
| 2 | -$13K | |
| 3 | -$7K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.04K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |